載入...
The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy remains the standard of care for patients with previously treated non-small cell lung cancer. However, few reports have compared the clinical benefits of second-line ICIs alone with those of ICIs combined with other therapies, including anti-...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8213016/ https://ncbi.nlm.nih.gov/pubmed/34150659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.690093 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|